Tumor cell–derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition
Journal of Clinical Investigation · 16.01.2025 · 135 (2)
DOI: 10.1172/jci177824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 19.11.2024. Verfasst von Kristen E Kay und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glioblastoma, Spermidine, Tumor Microenvironment, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
The glioblastoma (GBM) microenvironment is enriched in immunosuppressive factors that potently interfere with the function of cytotoxic T lymphocytes. Cancer cells can directly affect the immune system, but the mechanisms driving these interactions are not completely clear. Here, we demonstrate that the polyamine metabolite spermidine (SPD) was elevated in the GBM tumor microenvironment. Exogenous administration of SPD drove tumor aggressiveness in an immune-dependent manner in preclinical mouse models via reduction of CD8 + T cell frequency and reduced cytotoxic function. Knockdown of ornithine decarboxylase, the rate-limiting enzyme in SPD synthesis, did not affect cancer cell growth in vitro but did result in extended survival. Furthermore, patients with GBM with a more favorable outcome had a significant reduction in SPD compared with patients with a poor prognosis. Our results demonstrate that SPD functions as a cancer cell–derived metabolite that drives tumor progression by reducing CD8 + T cell numbers and function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Cleveland Clinic Lerner College of Medicine; and.
- Medical Scientist Training Program, School of Medicine; Case Western Reserve University, Cleveland, Ohio, USA.
- Rose Ella Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, Ohio, USA.
- Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- NINDS NIH HHS
- Cancer Council Victoria
- Perpetual
- Victorian Cancer Agency
- National Health and Medical Research Council
Zitieren
APA
Kay, K. E., Lee, J., Hong, E. S., Beilis, J., Dayal, S., Wesley, E. R., Mitchell, S., Wang, S. Z., Silver, D. J., Volovetz, J., Johnson, S., McGraw, M., Grabowski, M. M., Lu, T., Freytag, L., Narayana, V., Freytag, S., Best, S. A., Whittle, J. R., …, & Lathia, J. D. (2025). Tumor cell–derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition. Journal of Clinical Investigation, 135(2). https://doi.org/10.1172/jci177824
Vancouver
Kay KE, Lee J, Hong ES, Beilis J, Dayal S, Wesley ER, et al. Tumor cell–derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition. Journal of Clinical Investigation. 2025;135(2). doi:10.1172/jci177824
BibTeX
@article{Kay2025,
author = {Kay, Kristen E and Lee, Juyeun and Hong, Ellen S and Beilis, Julia and Dayal, Sahil and Wesley, Emily R and Mitchell, Sofia and Wang, Sabrina Z and Silver, Daniel J and Volovetz, Josephine and Johnson, Sadie and McGraw, Mary and Grabowski, Matthew M and Lu, Tianyao and Freytag, Lutz and Narayana, Vinod and Freytag, Saskia and Best, Sarah A and Whittle, James R and Wang, Zeneng and Reizes, Ofer and Yu, Jennifer S and Hazen, Stanley L and Brown, J Mark and Bayik, Defne and Lathia, Justin D},
title = {Tumor cell–derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {2},
doi = {10.1172/jci177824}
}
EUVIMED